Dr. Mark Lundie

Director of Medical Affairs, Rare Disease, Pfizer Canada

Mark received a PhD in Pharmacology from Queen’s University in 1995.  He joined Pfizer Canada in 1997 and has held a number of roles and, since 2013, is the current Director of Medical Affairs in the Rare Disease team. Mark has been directly involved with clinical trials, prior to joining industry and since within the industry.  He has served as a Board member for CTO since its inception, and he also volunteers on the Boards for Ontario Genomics and the Center for Probe Development and Commercialization.